Small molecule · developed by Aclaris Therapeutics
Modzatinib (ATI-2138) is a drug studied in lichen planus and atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07935590 | Phase 2 | Lichen Planus | Not yet recruiting | ACRS |
| NCT06585202 | Phase 2 | Atopic Dermatitis | Completed | ACRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lichen PlanusAtopic Dermatitis
See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACRS catalysts and pipeline →